<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0200504</article-id>
<article-id pub-id-type="publisher-id">PONE-D-18-08737</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Population biology</subject><subj-group><subject>Population metrics</subject><subj-group><subject>Death rates</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pulmonology</subject><subj-group><subject>Pneumonia</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Health care</subject><subj-group><subject>Health care facilities</subject><subj-group><subject>Hospitals</subject><subj-group><subject>Intensive care units</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Streptococcus</subject><subj-group><subject>Pneumococcus</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Streptococcus</subject><subj-group><subject>Pneumococcus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Streptococcus</subject><subj-group><subject>Pneumococcus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Public and occupational health</subject><subj-group><subject>Preventive medicine</subject><subj-group><subject>Vaccination and immunization</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Sepsis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Sepsis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Nutrition</subject><subj-group><subject>Diet</subject><subj-group><subject>Alcohol consumption</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Nutrition</subject><subj-group><subject>Diet</subject><subj-group><subject>Alcohol consumption</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia</article-title>
<alt-title alt-title-type="running-head">Twenty-year trend in mortality in pneumococcal CAP</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-4646-9838</contrib-id>
<name name-style="western">
<surname>Cillóniz</surname>
<given-names>Catia</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Liapikou</surname>
<given-names>Adamantia</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Martin-Loeches</surname>
<given-names>Ignacio</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>García-Vidal</surname>
<given-names>Carolina</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Gabarrús</surname>
<given-names>Albert</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ceccato</surname>
<given-names>Adrian</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Magdaleno</surname>
<given-names>Daniel</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Mensa</surname>
<given-names>Josep</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Marco</surname>
<given-names>Francesc</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5649-7699</contrib-id>
<name name-style="western">
<surname>Torres</surname>
<given-names>Antoni</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona—Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB)—SGR 911- Ciber de Enfermedades Respiratorias (Ciberes), Barcelona, Spain</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Respiratory Department, Sotiria Chest Diseases Hospital, Mesogion, Athens, Greece</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Multidisciplinary Intensive Care Research Organization (MICRO), St James's University Hospital, Department of Clinical Medicine, Trinity College, Dublin, Ireland</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Department of Infectious Disease, Hospital Clinic of Barcelona, Barcelona, Spain</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>Superior Medical School of the National Polytechnic Institute Mexico City, Mexico City, Mexico</addr-line></aff>
<aff id="aff006"><label>6</label> <addr-line>Department of Microbiology, Biomedical Diagnostic Center (CDB), ISGlobal, Barcelona Center for International Health Research (CRESIB), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Lazzeri</surname>
<given-names>Chiara</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Azienda Ospedaliero Universitaria Careggi, ITALY</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">atorres@clinic.cat</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>18</day>
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>13</volume>
<issue>7</issue>
<elocation-id>e0200504</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>3</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>6</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-year>2018</copyright-year>
<copyright-holder>Cillóniz et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0200504"/>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>There is only limited information on mortality over extended periods in hospitalized patients with pneumococcal community-acquired pneumonia (CAP). We aimed to evaluate the 30-day mortality and whether is changed over a 20-year period among immunocompetent adults hospitalized with pneumococcal CAP.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>We conducted a retrospective observational study of data that were prospectively collected at the Hospital Clinic of Barcelona of all adult patients hospitalized with diagnosis of pneumococcal CAP over a 20-year period. To aid analysis, results were divided into four periods of 5 years each (1997–2001, 2002–2006, 2007–2011, 2012–2016). The primary outcome was 30-day mortality, but secondary outcomes included intensive care unit (ICU) admission, lengths of hospital and ICU-stays, ICU-mortality, and need of mechanical ventilation.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>From a cohort of 6,403 patients with CAP, we analyzed the data for 1,120 (17%) adults with a diagnosis of pneumococcal CAP. Over time, we observed decreases in the rates of alcohol consumption, smoking, influenza vaccination, and older patients (age ≥65 years), but increases in admissions to ICU and the need for non-invasive mechanical ventilation. The overall 30-day mortality rate was 8% (95% confidence interval, 6%–9%; 84 of 1,120 patients) and did not change significantly between periods (p = 0.33). Although, we observed a decrease in ICU-mortality comparing the first period (26%) to the second one (10%), statistical differences disappeared with adjustment (p0.38).</p>
</sec>
<sec id="sec004">
<title>Conclusion</title>
<p>Over time, 30-day mortality of hospitalized pneumococcal CAP did not change significantly. Nor did it change in the propensity-adjusted multivariable analysis. Since mortality in pneumococcal pneumonia has remained unaltered for many years despite the availability of antimicrobial agents with proven in vitro activity, other non-antibiotic strategies should be investigated.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>This work was supported by Ciber de Enfermedades Respiratorias (CibeRes CB06/06/0028), 2009 Support to Research Groups of Catalonia 911, IDIBAPS (CERCA Programme / Generalitat de Catalunya). The funding sources had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.</funding-statement>
</funding-group>
<counts>
<fig-count count="3"/>
<table-count count="5"/>
<page-count count="16"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>Community-acquired pneumonia (CAP) continues to have high global morbidity and mortality rates, and is associated with considerable health costs[<xref ref-type="bibr" rid="pone.0200504.ref001">1</xref>,<xref ref-type="bibr" rid="pone.0200504.ref002">2</xref>]. Some recent published studies have reported that the incidence of CAP has risen in the last decade[<xref ref-type="bibr" rid="pone.0200504.ref003">3</xref>,<xref ref-type="bibr" rid="pone.0200504.ref004">4</xref>], with an increase in the rate of hospitalization. However, the trend in CAP mortality over recent decades is more controversial, and it was recently stated that mortality in patients hospitalized for CAP has declined over time[<xref ref-type="bibr" rid="pone.0200504.ref005">5</xref>–<xref ref-type="bibr" rid="pone.0200504.ref007">7</xref>]. Many clinical guidelinesfor CAP recommended by professional societies have been published since the early 1990s [<xref ref-type="bibr" rid="pone.0200504.ref008">8</xref>]. The aim of creating the guidelines was to a large extent to bring together all the data on CAP and to provide a tool for the management of CAP patients, since guidelines offer a means of standardizing care. The first set of guidelines for CAP was published by ATS in 1993[<xref ref-type="bibr" rid="pone.0200504.ref008">8</xref>]; other guidelines were subsequently published, updating the information with the results of new published studies on CAP, including IDSA 1998[<xref ref-type="bibr" rid="pone.0200504.ref009">9</xref>], ATS 2001[<xref ref-type="bibr" rid="pone.0200504.ref010">10</xref>], and the ATS/IDSA Joint Guidelines in 2007[<xref ref-type="bibr" rid="pone.0200504.ref011">11</xref>]. Two previous studies have demonstrated reductions in mortality after guideline implementation: one in hospitalized CAP[<xref ref-type="bibr" rid="pone.0200504.ref012">12</xref>]] and the other in severe CAP[<xref ref-type="bibr" rid="pone.0200504.ref013">13</xref>]. In fact, mortality has declined for a variety of conditions over recent decades, including for sepsis, myocardial infarction, and stroke[<xref ref-type="bibr" rid="pone.0200504.ref014">14</xref>,<xref ref-type="bibr" rid="pone.0200504.ref015">15</xref>], suggesting that better clinical management and improved healthcare are responsible[<xref ref-type="bibr" rid="pone.0200504.ref005">5</xref>–<xref ref-type="bibr" rid="pone.0200504.ref007">7</xref>].</p>
<p><italic>Streptococcus pneumoniae</italic> (pneumococcus) remains the most common pathogen in CAP[<xref ref-type="bibr" rid="pone.0200504.ref016">16</xref>,<xref ref-type="bibr" rid="pone.0200504.ref017">17</xref>], being associated with significant disease burden and a more severe disease course that requires more medical resources compared with non-pneumococcal CAP[<xref ref-type="bibr" rid="pone.0200504.ref018">18</xref>]. In Catalonia, the study setting, vaccination with 23-valent polysaccharide pneumococcal vaccine (PPV23) has been recommended for high-risk and older adults since the early 2000s[<xref ref-type="bibr" rid="pone.0200504.ref019">19</xref>]. The 7-valent pneumococcal conjugate vaccine (PCV7)was licensed in Spain for children In 2001, and it was replaced by the 13-valent pneumococcal conjugate vaccine (PCV13) in 2010[<xref ref-type="bibr" rid="pone.0200504.ref020">20</xref>]. In Catalonia in 2007 the estimated coverage of PCV7 was 47%, and the estimated coverage of PCV13 in 2013 was 55%[<xref ref-type="bibr" rid="pone.0200504.ref021">21</xref>,<xref ref-type="bibr" rid="pone.0200504.ref022">22</xref>]. However, except in the case of children with selected risk factors these vaccines were not financed by the Catalan Public Health System until July 2016, and were only available in the private sector. In Spain, the vaccines were not introduced into the recommended calendar until January 2017. Finally, in late 2012, the PCV13 was introduced for adults. A recent population-based cohort study involving more than two million people aged over 50 in Catalonia which investigated the clinical effectiveness of PCV13 vaccination in preventing hospitalization from pneumonia observed no clinical benefits from PCV13 vaccination. However, since in that study PCV13 coverage was low, vaccination was not randomized, and follow-up time was limited, the results must be interpreted with caution[<xref ref-type="bibr" rid="pone.0200504.ref023">23</xref>].</p>
<p>In a large homogeneous cohort of critically ill patients with pneumococcal CAP, Mongardon et al.[<xref ref-type="bibr" rid="pone.0200504.ref024">24</xref>] observed that septic shock occurred in 84% and that mechanical ventilation was required for 77%. The authors highlighted that, despite adequate antimicrobial therapy, pneumococcal pneumonia still has high early mortality (29%).</p>
<p>We hypothesized that mortality among patients hospitalized with pneumococcal CAP had decreased over time because of improvements in early detection, antibiotic therapy, clinical management, support bundles and improvement of health care systems. Thus, we aimed to analyze 30-day mortality rate and the trend in mortality for pneumococcal CAP in a large hospitalized adult population over a 20-year period. We also analyzed the main factors related to overall mortality from pneumococcal CAP.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Patients and methods</title>
<sec id="sec007">
<title>Study design</title>
<p>This was a retrospective observational study of data that were prospectively collected over 20 years in the Hospital Clinic, Barcelona. All adults with a clinical diagnosis of <italic>S</italic>. <italic>pneumoniae</italic> pneumonia between January 1996 and December 2016 were included. To aid analysis, we divided the study population into four cohorts by time period: 1997–2001, 2002–2006, 2007–2011, and 2012–2016. For the purpose of publication the Ethics Committee of the Hospital Clinic of Barcelona approved the study (Register: 2009/5451), and the need for written informed consent was waived because of the non-interventional design.</p>
</sec>
<sec id="sec008">
<title>Patients</title>
<p>We included all adults with a clinical diagnosis of pneumococcal pneumonia, including those coming from nursing homes. We excluded patients with active tuberculosis or immunosuppression, including those taking &gt;20 mg/day of prednisone (or daily equivalent) for at least 2 weeks, those receiving cytotoxic therapy, those known to have human immunodeficiency virus infection.</p>
</sec>
<sec id="sec009">
<title>Data collection, evaluation, and microbiological diagnosis</title>
<p>Demographic variables, comorbidities, and physiological parameters were collected in the emergency department within 24 hours of admission. We also calculated the pneumonia severity index (PSI), the CURB-65 (Consciousness, Urea, Respiratory rate, Blood pressure, 65 years old), and the sequential organ failure assessment (SOFA) scores at admission[<xref ref-type="bibr" rid="pone.0200504.ref025">25</xref>–<xref ref-type="bibr" rid="pone.0200504.ref027">27</xref>]. During hospitalization, we recorded whether the patients had complications such as multilobar infiltration, pleural effusions, acute respiratory distress syndrome(ARDS)[<xref ref-type="bibr" rid="pone.0200504.ref028">28</xref>]], septic shock[<xref ref-type="bibr" rid="pone.0200504.ref029">29</xref>], or acute renal failure[<xref ref-type="bibr" rid="pone.0200504.ref030">30</xref>]. Further details are reported elsewhere[<xref ref-type="bibr" rid="pone.0200504.ref017">17</xref>].</p>
<p>The etiology of pneumococcal pneumonia was determined by positive results in any of the following: valid sputum culture; valid blood culture; pleural fluid and transthoracic needle aspiration cultures; urinary antigen for <italic>S</italic>. <italic>pneumoniae</italic>; bacterial growth exceeding 10<sup>3</sup>, 10<sup>4</sup>, or 10<sup>5</sup> colony forming units (CFU)/mL in protective brush sample, bronchoalveolar lavage cultures or tracheobronchial aspirate, respectively. Definition and additional details are shown in Supplementary Material.</p>
</sec>
<sec id="sec010">
<title>Primary and secondary outcomes</title>
<p>The primary outcome was 30-day mortality, and the secondary outcomes were the lengths of hospital and ICU stays, admission to ICU, mortality in ICU, and need for mechanical ventilation. Early mortality was defined as the mortality in the first 72 hours of admission and late mortality was defined as the mortality after 72 hours to 30 days of admission.</p>
</sec>
<sec id="sec011">
<title>Statistical analysis</title>
<p>We report the number and percentage of patients for categorical variables, the mean and standard deviation (SD) for normally distributed data, and the median and interquartile range (IQR) for non-normally distributed data. To reduce the variability and random noise in year-by-year data we divided the study into four time periods of five years each, defining 1997–2001 as the reference period. We estimated the overall 30-day mortality and the mortality in each of the four periods, reporting them with 95% confidence intervals (CIs)[<xref ref-type="bibr" rid="pone.0200504.ref031">31</xref>]. Trends in associated factors were analyzed using the Mantel–Hansel test for categorical variables and linear regression for continuous variables. Time to 30-day mortality was analyzed by Kaplan–Meier survival curves and compared using the Gehan–Breslow–Wilcoxon test. Cox proportional hazard regression analyses[<xref ref-type="bibr" rid="pone.0200504.ref032">32</xref>] were performed to determine the influence of risk factors on the 30-day mortality. First, each risk factor was tested individually (see Methods in Supplementary Material the full list of variables). Second, a propensity score (PS)[<xref ref-type="bibr" rid="pone.0200504.ref033">33</xref>] was developed for empiric antibiotic use because antibiotic therapy were not randomly administered and could have resulted in confounding and selection bias[<xref ref-type="bibr" rid="pone.0200504.ref034">34</xref>]. Finally, the scores, admission period, and empiric antibiotic therapy were incorporated in the multivariable Cox regression model to predict 30-day mortality, together with all risk factors showing an association in the univariable analyses by stepwise backward elimination (p<sub>in</sub> &lt; 0.05, p<sub>out</sub> &gt; 0.10). We calculated the hazard ratios (HRs) and their 95% CIs. We calculated the area under the receiver operating characteristic curve (AUC) for the multivariable model to predict 30-day mortality. Internal validity of the prediction model was assessed by ordinary nonparametric bootstrapping with 1000 bootstrap samples and bias-corrected, accelerated 95% CIs[<xref ref-type="bibr" rid="pone.0200504.ref035">35</xref>]. Also, to determine the influence of the risk factors on ICU mortality, the analyses were repeated on the subset of patients admitted to ICU.</p>
<p>We used multiple imputation method for missing data for handling missing data in multivariable analyses[<xref ref-type="bibr" rid="pone.0200504.ref036">36</xref>]. The level of significance was set at 0·05 (two-tailed). All analyses were performed with IBM SPSS Statistics 23·0 (Armonk, New York).</p>
</sec>
</sec>
<sec id="sec012" sec-type="results">
<title>Results</title>
<sec id="sec013">
<title>Patients’ characteristics</title>
<p>Of the 6,403 patients with CAP admitted during the study period, 1,120 (18%) were diagnosed with pneumococcal pneumonia and included in the study “<xref ref-type="fig" rid="pone.0200504.g001">Fig 1</xref>”. Our cohort comprised 694 males (62%) and 426 females (38%), with a mean (SD) age of 66.9 (17.7) years; notably, 701 (63%) were aged ≥65 years.</p>
<fig id="pone.0200504.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0200504.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flow chart of study population.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0200504.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec014">
<title>Changes in patients’ characteristics over time</title>
<p>The main clinical characteristics of the study population are summarized by study period in “<xref ref-type="table" rid="pone.0200504.t001">Table 1</xref>”. There were no differences in sex between periods, but there were differences in the distribution of cases by age, smoking status, and alcohol consumption, which were significantly higher in the first period compared with later periods.</p>
<table-wrap id="pone.0200504.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0200504.t001</object-id>
<label>Table 1</label> <caption><title>Patients’ characteristics by study period.</title></caption>
<alternatives>
<graphic id="pone.0200504.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0200504.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="justify">Variable</th>
<th align="justify">1997–2001<break/>(n = 285)</th>
<th align="justify">2002–2006<break/>(n = 340)</th>
<th align="justify">2007–2011<break/>(n = 291)</th>
<th align="justify">2012–2016<break/>(n = 204)</th>
<th align="justify">P-value for trend</th>
</tr>
</thead>
<tbody>
<tr>
<td align="justify">Age, mean (SD), years</td>
<td align="justify">67.4 (16.4)</td>
<td align="justify">66.9 (18.0)</td>
<td align="justify">65.9 (18.2)</td>
<td align="justify">67.6 (18.4)</td>
<td align="justify">0.82</td>
</tr>
<tr>
<td align="justify">Age ≥65 years, n (%)</td>
<td align="justify">194 (68)</td>
<td align="justify">215 (63)</td>
<td align="justify">168 (58)</td>
<td align="justify">124 (61)</td>
<td align="justify"><bold>0.029</bold></td>
</tr>
<tr>
<td align="justify">Male sex, n (%)</td>
<td align="justify">205 (72)</td>
<td align="justify">186 (55)</td>
<td align="justify">173 (60)</td>
<td align="justify">130 (64)</td>
<td align="justify">0.095</td>
</tr>
<tr>
<td align="justify">Current smoker, n (%)</td>
<td align="justify">99 (35)</td>
<td align="justify">96 (28)</td>
<td align="justify">80 (28)</td>
<td align="justify">47 (23)</td>
<td align="justify"><bold>0.006</bold></td>
</tr>
<tr>
<td align="justify">Current alcohol consumer, n (%)</td>
<td align="justify">72 (26)</td>
<td align="justify">60 (18)</td>
<td align="justify">47 (17)</td>
<td align="justify">30 (15)</td>
<td align="justify"><bold>0.002</bold></td>
</tr>
<tr>
<td align="justify">Previous antibiotic, n (%)</td>
<td align="justify">31 (11)</td>
<td align="justify">61 (18)</td>
<td align="justify">41 (16)</td>
<td align="justify">32 (16)</td>
<td align="justify">0.18</td>
</tr>
<tr>
<td align="justify">Influenza vaccine, n (%)</td>
<td align="justify">20 (32)</td>
<td align="justify">127 (42)</td>
<td align="justify">118 (47)</td>
<td align="justify">49 (25)</td>
<td align="justify"><bold>0.030</bold></td>
</tr>
<tr>
<td align="justify">Pneumococcal vaccine, n (%)</td>
<td align="justify">11 (18)</td>
<td align="justify">45 (15)</td>
<td align="justify">40 (16)</td>
<td align="justify">36 (19)</td>
<td align="justify">0.51</td>
</tr>
<tr>
<td align="justify">Previous inhaled corticosteroids, n (%)</td>
<td align="justify">57 (20)</td>
<td align="justify">67 (20)</td>
<td align="justify">77 (27)</td>
<td align="justify">33 (17)</td>
<td align="justify">0.87</td>
</tr>
<tr>
<td align="justify">Previous systemic corticosteroids, n (%)</td>
<td align="justify">12 (12)</td>
<td align="justify">27 (8)</td>
<td align="justify">9 (3)</td>
<td align="justify">10 (5)</td>
<td align="justify"><bold>0.004</bold></td>
</tr>
<tr>
<td align="justify">Previous episode of pneumonia (last year), n (%)</td>
<td align="justify">28 (11)</td>
<td align="justify">71 (21)</td>
<td align="justify">26 (10)</td>
<td align="justify">14 (7)</td>
<td align="justify"><bold>0.012</bold></td>
</tr>
<tr>
<td align="justify">Comorbidities, n (%)<xref ref-type="table-fn" rid="t001fn002"><sup>a</sup></xref></td>
<td align="justify">221 (78)</td>
<td align="justify">240 (71)</td>
<td align="justify">187 (64)</td>
<td align="justify">131 (64)</td>
<td align="justify"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="justify">  Chronic respiratory disease</td>
<td align="justify">172 (61)</td>
<td align="justify">160 (47)</td>
<td align="justify">127 (45)</td>
<td align="justify">65 (33)</td>
<td align="justify"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="justify">  COPD</td>
<td align="justify">138 (49)</td>
<td align="justify">98 (29)</td>
<td align="justify">74 (26)</td>
<td align="justify">39 (20)</td>
<td align="justify"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="justify">  Asthma</td>
<td align="justify">9 (3)</td>
<td align="justify">24 (7)</td>
<td align="justify">16 (6)</td>
<td align="justify">7 (4)</td>
<td align="justify">0.88</td>
</tr>
<tr>
<td align="justify">  Bronchiectasis</td>
<td align="justify">9 (3)</td>
<td align="justify">7 (2)</td>
<td align="justify">11 (4)</td>
<td align="justify">1 (1)</td>
<td align="justify">0.28</td>
</tr>
<tr>
<td align="justify">  Other<xref ref-type="table-fn" rid="t001fn003"><sup>b</sup></xref></td>
<td align="justify">16 (6)</td>
<td align="justify">31 (9)</td>
<td align="justify">26 (9)</td>
<td align="justify">18 (9)</td>
<td align="justify">0.15</td>
</tr>
<tr>
<td align="justify">  Chronic cardiovascular disease</td>
<td align="justify">47 (17)</td>
<td align="justify">52 (15)</td>
<td align="justify">41 (14)</td>
<td align="justify">11 (6)</td>
<td align="justify"><bold>0.001</bold></td>
</tr>
<tr>
<td align="justify">  Diabetes mellitus</td>
<td align="justify">55 (19)</td>
<td align="justify">78 (23)</td>
<td align="justify">41 (14)</td>
<td align="justify">40 (20)</td>
<td align="justify">0.46</td>
</tr>
<tr>
<td align="justify">  Neurological disease</td>
<td align="justify">32 (11)</td>
<td align="justify">42 (13)</td>
<td align="justify">46 (17)</td>
<td align="justify">35 (18)</td>
<td align="justify"><bold>0.016</bold></td>
</tr>
<tr>
<td align="justify">  Chronic renal disease</td>
<td align="justify">23 (8)</td>
<td align="justify">17 (5)</td>
<td align="justify">21 (7)</td>
<td align="justify">17 (9)</td>
<td align="justify">0.64</td>
</tr>
<tr>
<td align="justify">  Chronic liver disease</td>
<td align="justify">30 (11)</td>
<td align="justify">23 (7)</td>
<td align="justify">15 (5)</td>
<td align="justify">16 (8)</td>
<td align="justify">0.15</td>
</tr>
<tr>
<td align="justify">Nursing-home, n (%)</td>
<td align="justify">9 (3)</td>
<td align="justify">16 (5)</td>
<td align="justify">24 (8)</td>
<td align="justify">10 (5)</td>
<td align="justify">0.093</td>
</tr>
<tr>
<td align="justify">Creatinine, mg/dL, median (IQR)</td>
<td align="justify">1.1 (0.9; 1.4)</td>
<td align="justify">1.2 (1; 1.6)</td>
<td align="justify">1 (0.8; 1.5)</td>
<td align="justify">1.2 (0.9; 1.7)</td>
<td align="justify">0.47</td>
</tr>
<tr>
<td align="justify">C-reactive protein, mg/dL, median (IQR)</td>
<td align="justify">169 (85; 296)</td>
<td align="justify">221 (111; 317)</td>
<td align="justify">242 (147; 308)</td>
<td align="justify">246 (148; 290)</td>
<td align="justify">0.59</td>
</tr>
<tr>
<td align="justify">PaO<sub>2</sub>/FiO<sub>2</sub>, median (IQR)</td>
<td align="justify">276 (229; 314)</td>
<td align="justify">281 (243; 319)</td>
<td align="justify">267 (218; 301)</td>
<td align="justify">266 (203; 308)</td>
<td align="justify"><bold>0.002</bold></td>
</tr>
<tr>
<td align="justify">SOFA score, median (IQR)</td>
<td align="justify">2 (2; 4)</td>
<td align="justify">3 (2; 4)</td>
<td align="justify">2 (1; 3)</td>
<td align="justify">2 (1; 3)</td>
<td align="justify"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="justify">SOFA score ≥5, n (%)<xref ref-type="table-fn" rid="t001fn004"><sup>c</sup></xref></td>
<td align="justify">53 (19)</td>
<td align="justify">54 (16)</td>
<td align="justify">35 (12)</td>
<td align="justify">12 (8)</td>
<td align="justify"><bold>0.002</bold></td>
</tr>
<tr>
<td align="justify">PSI score, median (IQR)</td>
<td align="justify">102 (80; 127)</td>
<td align="justify">100 (77; 126)</td>
<td align="justify">100 (75; 120)</td>
<td align="justify">105 (80; 125)</td>
<td align="justify">0.43</td>
</tr>
<tr>
<td align="justify">PSI risk class IV–V, n (%)<xref ref-type="table-fn" rid="t001fn005"><sup>d</sup></xref></td>
<td align="justify">173 (62)</td>
<td align="justify">188 (60)</td>
<td align="justify">107 (55)</td>
<td align="justify">59 (64)</td>
<td align="justify">0.57</td>
</tr>
<tr>
<td align="justify">CURB-65 risk class 3–5, n (%)<xref ref-type="table-fn" rid="t001fn006"><sup>e</sup></xref></td>
<td align="justify">74 (26)</td>
<td align="justify">88 (26)</td>
<td align="justify">51 (20)</td>
<td align="justify">31 (21)</td>
<td align="justify">0.090</td>
</tr>
<tr>
<td align="justify">Pneumococcal bacteremia, n (%)</td>
<td align="justify">104 (39)</td>
<td align="justify">113 (41)</td>
<td align="justify">93 (37)</td>
<td align="justify">70 (41)</td>
<td align="justify">0.90</td>
</tr>
<tr>
<td align="justify">Invasive pneumococcal pneumonia, n (%)</td>
<td align="justify">111 (41)</td>
<td align="justify">121 (42)</td>
<td align="justify">101 (39)</td>
<td align="justify">73 (42)</td>
<td align="justify">0.98</td>
</tr>
<tr>
<td align="justify">Pleural effusion, n (%)</td>
<td align="justify">49 (17)</td>
<td align="justify">59 (17)</td>
<td align="justify">68 (24)</td>
<td align="justify">30 (16)</td>
<td align="justify">0.64</td>
</tr>
<tr>
<td align="justify">Multilobar, n (%)</td>
<td align="justify">75 (26)</td>
<td align="justify">97 (29)</td>
<td align="justify">76 (26)</td>
<td align="justify">66 (32)</td>
<td align="justify">0.28</td>
</tr>
<tr>
<td align="justify">ARDS, n (%)</td>
<td align="justify">12 (4)</td>
<td align="justify">13 (4)</td>
<td align="justify">19 (7)</td>
<td align="justify">16 (8)</td>
<td align="justify"><bold>0.026</bold></td>
</tr>
<tr>
<td align="justify">Acute renal failure, n (%)</td>
<td align="justify">80 (28)</td>
<td align="justify">115 (34)</td>
<td align="justify">83 (29)</td>
<td align="justify">72 (36)</td>
<td align="justify">0.21</td>
</tr>
<tr>
<td align="justify">Septic shock, n (%)</td>
<td align="justify">27 (9)</td>
<td align="justify">34 (10)</td>
<td align="justify">50 (17)</td>
<td align="justify">31 (15)</td>
<td align="justify"><bold>0.005</bold></td>
</tr>
<tr>
<td align="justify">Empiric antibiotic therapy, n (%)</td>
<td align="justify"/>
<td align="justify"/>
<td align="justify"/>
<td align="justify"/>
<td align="justify"/>
</tr>
<tr>
<td align="justify">  Monotherapy</td>
<td align="justify">50 (18)</td>
<td align="justify">81 (24)</td>
<td align="justify">60 (21)</td>
<td align="justify">33 (16)</td>
<td align="justify">0.63</td>
</tr>
<tr>
<td align="justify">  Fluoroquinolones</td>
<td align="justify">8 (3)</td>
<td align="justify">68 (20)</td>
<td align="justify">50 (17)</td>
<td align="justify">19 (9)</td>
<td align="justify"><bold>0.025</bold></td>
</tr>
<tr>
<td align="justify">  β-lactams</td>
<td align="justify">34 (12)</td>
<td align="justify">11 (3)</td>
<td align="justify">10 (3)</td>
<td align="justify">12 (6)</td>
<td align="justify"><bold>0.003</bold></td>
</tr>
<tr>
<td align="justify">  Other therapy</td>
<td align="justify">8 (3)</td>
<td align="justify">2 (1)</td>
<td align="justify">0 (0)</td>
<td align="justify">2 (1)</td>
<td align="justify"><bold>0.020</bold></td>
</tr>
<tr>
<td align="justify">  Combination therapies</td>
<td align="justify">232 (82)</td>
<td align="justify">259 (76)</td>
<td align="justify">230 (79)</td>
<td align="justify">169 (84)</td>
<td align="justify">0.63</td>
</tr>
<tr>
<td align="justify">  β-lactams plus macrolides</td>
<td align="justify">185 (66)</td>
<td align="justify">148 (44)</td>
<td align="justify">87 (30)</td>
<td align="justify">97 (48)</td>
<td align="justify"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="justify">  β-lactams plus fluoroquinolones</td>
<td align="justify">4 (1)</td>
<td align="justify">84 (25)</td>
<td align="justify">119 (41)</td>
<td align="justify">57 (28)</td>
<td align="justify"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="justify">  Other combination therapies</td>
<td align="justify">43 (15)</td>
<td align="justify">27 (8)</td>
<td align="justify">24 (8)</td>
<td align="justify">15 (7)</td>
<td align="justify"><bold>0.005</bold></td>
</tr>
<tr>
<td align="justify">Appropriate empiric treatment, n (%)</td>
<td align="justify">274 (97)</td>
<td align="justify">328 (97)</td>
<td align="justify">280 (97)</td>
<td align="justify">198 (99)</td>
<td align="justify">0.63</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>Abbreviations: ARDS indicates acute respiratory distress syndrome; COPD = chronic obstructive pulmonary disease; CURB-65 = Consciousness, Urea, Respiratory rate, Blood pressure, 65 years old; IQR, interquartile range; PSI, pneumonia severity index; PaO<sub>2</sub>/FiO<sub>2</sub> = arterial oxygen tension to inspired oxygen fraction ratio; SD, standard deviation; SOFA, sequential organ failure assessment. Percentages calculated on non-missing data.</p></fn>
<fn id="t001fn002"><p><sup>a</sup> May have &gt;1 comorbid condition.</p></fn>
<fn id="t001fn003"><p><sup>b</sup> Other respiratory diseases include sequelae of pulmonary tuberculosis, pulmonary hypertension, and interstitial lung disease.</p></fn>
<fn id="t001fn004"><p><sup>c</sup> Optimal cut-off value to predict 30-day mortality using ROC curves.</p></fn>
<fn id="t001fn005"><p><sup>d</sup> Stratified according to 30-day risk mortality for community-acquired pneumonia: risk classes I–III (≤90 points) have low mortality and risk classes IV–V (&gt;90 points) have the highest mortality.</p></fn>
<fn id="t001fn006"><p><sup>e</sup> Stratified according to 30-day risk mortality for community-acquired pneumonia: risk classes 0–2 have low mortality and risk classes 3–5 have the highest mortality.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Regarding severity, there was a progressive increase in presentations with ARDS (4% in the first period to 8% in the last period; p = 0.026) and patients with septic shock (9% in the first period to 15% in the last period; p = 0.005).</p>
<p>The prevalence of pneumococcal CAP did not change significantly over time, only varying between 39% and 42% (p = 0.98) “<xref ref-type="table" rid="pone.0200504.t002">Table 2</xref>”. From 2002, 167 of 420 invasive isolates (40%) were available for serotyping, and the percentages of cases covered by the pneumococcal conjugate vaccine (PCV13) decreased from 94% in the second period to 56% in the last period (p = 0.001). Regarding empiric antibiotic therapy, we observed no differences in prescriptions of monotherapy and combination therapy between periods. The adequacy of antibiotic therapy was similar among periods (97%).</p>
<table-wrap id="pone.0200504.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0200504.t002</object-id>
<label>Table 2</label> <caption><title>Samples for microbiological diagnosis of pneumococcal pneumonia by study period.</title></caption>
<alternatives>
<graphic id="pone.0200504.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0200504.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="justify">Microbiological test</th>
<th align="justify">1997–2001<break/>(n = 285)</th>
<th align="justify">2002–2006<break/>(n = 340)</th>
<th align="justify">2007–2011<break/>(n = 291)</th>
<th align="justify">2012–2016<break/>(n = 204)</th>
<th align="justify">P-value for trend</th>
</tr>
</thead>
<tbody>
<tr>
<td align="justify">Urinary antigen test for pneumococcus</td>
<td align="justify">111/120 (93)</td>
<td align="justify">222/255 (87)</td>
<td align="justify">199/238 (84)</td>
<td align="justify">131/168 (78)</td>
<td align="justify"><bold>0.001</bold></td>
</tr>
<tr>
<td align="justify">Blood culture</td>
<td align="justify">104/268 (39)</td>
<td align="justify">113/279 (41)</td>
<td align="justify">93/252 (37)</td>
<td align="justify">70/170 (41)</td>
<td align="justify">0.90</td>
</tr>
<tr>
<td align="justify">Pleural fluid culture</td>
<td align="justify">12/37 (32)</td>
<td align="justify">8/32 (25)</td>
<td align="justify">13/48 (27)</td>
<td align="justify">7/23 (30)</td>
<td align="justify">0.81</td>
</tr>
<tr>
<td align="justify">Sputum culture</td>
<td align="justify">131/189 (69)</td>
<td align="justify">61/197 (31)</td>
<td align="justify">59/155 (38)</td>
<td align="justify">35/96 (37)</td>
<td align="justify"><bold>0.001</bold></td>
</tr>
<tr>
<td align="justify">Bronchoalveolar aspirate</td>
<td align="justify">26/42 (62)</td>
<td align="justify">8/26 (31)</td>
<td align="justify">16/42 (38)</td>
<td align="justify">6/19 (32)</td>
<td align="justify"><bold>0.005</bold></td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>Data are shown as number of patients with pneumonia due to <italic>Streptococcus pneumoniae</italic> (pneumococcus) / number of patients for each microbiological examination performed (%).</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec015">
<title>Clinical outcomes</title>
<p>The most frequent causes of death were acute respiratory failure secondary to pneumonia (54%; n = 45), multiorgan failure associated with septic shock (36%; n = 30), and acute cardiac events related to pneumonia (8%; n = 7).</p>
<p>The overall 30-day mortality rate among all 1,120 patients was 8% (95% CI, 6%–9%; n = 84). By subgroup, the 30-day mortality rates were as follows. In the 701 patients aged ≥65 years, it was 10% (95% CI, 8%–12%; n = 69) compared with 4% (95% CI, 2%–5%; n = 15) in the 419 patients aged &lt;65 years (p &lt; 0.001). In the 406 cases with invasive pneumococcal CAP it was 10% (95% CI, 7%–13%; n = 40) compared with 6% (95% CI, 4%–8%; n = 36) in the 579 patients with non-invasive pneumococcal CAP (p = 0.035). Finally, the 30-day mortality among 815 patients hospitalized to conventional wards was 4% (95% CI, 2%–5%; n = 30), but this increased to 18% (95% CI, 13%–22%; n = 53) among the 302 patients admitted to ICU (p &lt; 0.001).</p>
<p>The 30-day mortality rate also changed with the number of comorbidities. In 779 patients with at least one comorbidity, the rate was 9% (95% CI, 7%–11%; n = 71) compared with 4% (95% CI, 2%–6%; n = 13) among 338 healthy patients (p = 0.002). As expected, compared with the 30-day mortality of 7% (95% CI, 5%–9%; n = 75) among the 1,080 patients receiving adequate antibiotic therapy, mortality increased to 25% (95% CI, 10%–40%; n = 8) among the 32 patients receiving inadequate antibiotic therapy (p &lt; 0.001).</p>
<p>The frequency of mortality in the first 72 hours of admission (1.4% in the first period to 1.5% in the last period; p 0.89) and the frequency of mortality after 72 hours to 30 days (7% in the first period to 8% in the last period; p 0.33) did not change over time. Outcomes by study period are shown in “<xref ref-type="table" rid="pone.0200504.t003">Table 3</xref>”.</p>
<table-wrap id="pone.0200504.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0200504.t003</object-id>
<label>Table 3</label> <caption><title>Outcomes by study period.</title></caption>
<alternatives>
<graphic id="pone.0200504.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0200504.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="justify">Variable</th>
<th align="justify">1997–2001<break/>(n = 285)</th>
<th align="justify">2002–2006<break/>(n = 340)</th>
<th align="justify">2007–2011<break/>(n = 291)</th>
<th align="justify">2012–2016<break/>(n = 204)</th>
<th align="justify">P-value for trend</th>
</tr>
</thead>
<tbody>
<tr>
<td align="justify">30-day mortality, n (%)</td>
<td align="justify">24 (8)</td>
<td align="justify">16 (5)</td>
<td align="justify">24 (8)</td>
<td align="justify">20 (10)</td>
<td align="justify">0.33</td>
</tr>
<tr>
<td align="justify">Length of hospital stay, median (IQR), days</td>
<td align="justify">8 (5; 11)</td>
<td align="justify">8 (5; 12.5)</td>
<td align="justify">9 (6; 12)</td>
<td align="justify">8 (6; 13)</td>
<td align="justify">0.070</td>
</tr>
<tr>
<td align="justify">ICU admission, n (%)</td>
<td align="justify">57 (20)</td>
<td align="justify">78 (23)</td>
<td align="justify">100 (34)</td>
<td align="justify">67 (33)</td>
<td align="justify"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="justify">  ICU mortality, n (%)<xref ref-type="table-fn" rid="t003fn002"><sup>a</sup></xref></td>
<td align="justify">15 (26)</td>
<td align="justify">8 (10)</td>
<td align="justify">11 (11)</td>
<td align="justify">7 (10)</td>
<td align="justify"><bold>0.023</bold></td>
</tr>
<tr>
<td align="justify">  Length of stay in ICU, median (IQR), days<xref ref-type="table-fn" rid="t003fn002"><sup>a</sup></xref></td>
<td align="justify">12 (8; 24)</td>
<td align="justify">14 (9; 27)</td>
<td align="justify">11 (8; 17.5)</td>
<td align="justify">12 (8; 19)</td>
<td align="justify">0.20</td>
</tr>
<tr>
<td align="justify">Mechanical ventilation, n (%)<xref ref-type="table-fn" rid="t003fn003"><sup>b</sup></xref></td>
<td align="justify"/>
<td align="justify"/>
<td align="justify"/>
<td align="justify"/>
<td align="justify">0.78</td>
</tr>
<tr>
<td align="justify">  Not ventilated</td>
<td align="justify">249 (87)</td>
<td align="justify">292 (89)</td>
<td align="justify">217 (84)</td>
<td align="justify">139 (86)</td>
<td align="justify">0.31</td>
</tr>
<tr>
<td align="justify">  Non-invasive</td>
<td align="justify">0</td>
<td align="justify">14 (4)</td>
<td align="justify">17 (7)</td>
<td align="justify">11 (7)</td>
<td align="justify"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="justify">  Invasive</td>
<td align="justify">36 (13)</td>
<td align="justify">23 (7)</td>
<td align="justify">26 (10)</td>
<td align="justify">11 (7)</td>
<td align="justify">0.11</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p>Abbreviations: ICU, intensive care unit; IQR, interquartile range. Percentages calculated on non-missing data.</p></fn>
<fn id="t003fn002"><p><sup>a</sup> 57 patients in the 1997–2001 period, 78 patients in the 2002–2006 period, 100 in the 2007–2011 period, and 67 patients in the 2012–2016 period were used to calculate the percentages and the medians (IQR).</p></fn>
<fn id="t003fn003"><p><sup>b</sup> Patients who initially received non-invasive ventilation but subsequently needed intubation were included in the invasive mechanical ventilation group.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The overall 30-day mortality rate did not change significantly between periods (p = 0.33), ranging from 8% in the first period to 10% in the last period “<xref ref-type="fig" rid="pone.0200504.g002">Fig 2</xref>”. Kaplan–Meier survival curves depicting 30-day mortality rates as a function of period are shown in “<xref ref-type="fig" rid="pone.0200504.g003">Fig 3</xref>”. There was a progressive increase in patients requiring ICU admission (20% in the first period to 33% in the last period; p &lt; 0.001) and non-invasive mechanical ventilation (NIV) (0% in the first period to 7% in the last period; p &lt; 0.001). The use of invasive mechanical ventilation did not change between the four periods. ICU mortality was 26% in the first period, it dropped to 10% in the second period, and remained stable thereafter (p = 0.023). However, after adjusted by propensity-adjusted multivariable analysis, study period was not associated with ICU mortality.</p>
<fig id="pone.0200504.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0200504.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Rate of 30-day mortality per period.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0200504.g002" xlink:type="simple"/>
</fig>
<fig id="pone.0200504.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0200504.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Kaplan-Meier analysis on the effect of period on time to death.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0200504.g003" xlink:type="simple"/>
</fig>
<p>In the subgroup of patients receiving NIV, ICU mortality changed non-significantly from 0% in the first period to 9% in the last period (p = 0.23). By Kaplan–Meier analysis, time to death in the ICU and time to death of patients receiving NIV in the ICU did not differ significantly between periods (p = 0.17 and p = 0.76, respectively) (<xref ref-type="supplementary-material" rid="pone.0200504.s001">S1 Fig</xref>).</p>
</sec>
<sec id="sec016">
<title>Factors associated with 30-Day mortality and ICU mortality</title>
<p>The univariable Cox regression analysis revealed several variables to be significantly associated with 30-day mortality “<xref ref-type="table" rid="pone.0200504.t004">Table 4</xref>”. Among these, age ≥65 years, diabetes mellitus, SOFA score ≥5, and requirement for mechanical ventilation (non-invasive and invasive) were independently associated with 30-day mortality in the propensity-adjusted multivariable analysis. Period of admission was not significantly associated with 30-day mortality after adjustment for potential confounders.</p>
<table-wrap id="pone.0200504.t004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0200504.t004</object-id>
<label>Table 4</label> <caption><title>Significant univariable and multivariable Cox regression analyses for the prediction of 30-day mortality.</title></caption>
<alternatives>
<graphic id="pone.0200504.t004g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0200504.t004" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="justify" rowspan="2" style="background-color:#FFFFFF">Variable</th>
<th align="justify" colspan="3" style="background-color:#FFFFFF">Univariable<xref ref-type="table-fn" rid="t004fn002"><sup>a</sup></xref></th>
<th align="justify" colspan="3" style="background-color:#FFFFFF">Multivariable<xref ref-type="table-fn" rid="t004fn003"><sup>b</sup></xref></th>
</tr>
<tr>
<th align="justify" style="background-color:#FFFFFF">HR</th>
<th align="justify" style="background-color:#FFFFFF">95% CI</th>
<th align="justify" style="background-color:#FFFFFF">P-value</th>
<th align="justify" style="background-color:#FFFFFF">HR</th>
<th align="justify" style="background-color:#FFFFFF">95% CI</th>
<th align="justify" style="background-color:#FFFFFF">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="justify" style="background-color:#FFFFFF">Period of admission<xref ref-type="table-fn" rid="t004fn004"><sup>c</sup></xref></td>
<td align="justify" style="background-color:#FFFFFF"/>
<td align="justify" style="background-color:#FFFFFF"/>
<td align="justify" style="background-color:#FFFFFF">0.12</td>
<td align="justify" style="background-color:#FFFFFF"/>
<td align="justify" style="background-color:#FFFFFF"/>
<td align="justify" style="background-color:#FFFFFF">0.12</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">  1997–2001</td>
<td align="justify" style="background-color:#FFFFFF">1.00</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">1.00</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">  2002–2006</td>
<td align="justify" style="background-color:#FFFFFF">0.54</td>
<td align="justify" style="background-color:#FFFFFF">0.29 to 1.02</td>
<td align="justify" style="background-color:#FFFFFF">0.060</td>
<td align="justify" style="background-color:#FFFFFF">1.67</td>
<td align="justify" style="background-color:#FFFFFF">0.15 to 18.95</td>
<td align="justify" style="background-color:#FFFFFF">0.68</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">  2007–2011</td>
<td align="justify" style="background-color:#FFFFFF">0.97</td>
<td align="justify" style="background-color:#FFFFFF">0.55 to 1.71</td>
<td align="justify" style="background-color:#FFFFFF">0.93</td>
<td align="justify" style="background-color:#FFFFFF">4.03</td>
<td align="justify" style="background-color:#FFFFFF">0.20 to 81.23</td>
<td align="justify" style="background-color:#FFFFFF">0.36</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">  2012–2016</td>
<td align="justify" style="background-color:#FFFFFF">1.17</td>
<td align="justify" style="background-color:#FFFFFF">0.65 to 2.12</td>
<td align="justify" style="background-color:#FFFFFF">0.60</td>
<td align="justify" style="background-color:#FFFFFF">3.09</td>
<td align="justify" style="background-color:#FFFFFF">0.46 to 20.97</td>
<td align="justify" style="background-color:#FFFFFF">0.25</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">Age ≥65 years</td>
<td align="justify" style="background-color:#FFFFFF">2.83</td>
<td align="justify" style="background-color:#FFFFFF">1.62 to 4.95</td>
<td align="justify" style="background-color:#FFFFFF">&lt;0.001</td>
<td align="justify" style="background-color:#FFFFFF">2.93</td>
<td align="justify" style="background-color:#FFFFFF">1.63 to 5.27</td>
<td align="justify" style="background-color:#FFFFFF">&lt;0.001</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">Previous systemic corticosteroids</td>
<td align="justify" style="background-color:#FFFFFF">1.51</td>
<td align="justify" style="background-color:#FFFFFF">0.94 to 2.42</td>
<td align="justify" style="background-color:#FFFFFF">0.090</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">Chronic renal disease</td>
<td align="justify" style="background-color:#FFFFFF">2.58</td>
<td align="justify" style="background-color:#FFFFFF">1.43 to 4.67</td>
<td align="justify" style="background-color:#FFFFFF">0.002</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">Chronic liver disease</td>
<td align="justify" style="background-color:#FFFFFF">2.10</td>
<td align="justify" style="background-color:#FFFFFF">1.14 to 3.87</td>
<td align="justify" style="background-color:#FFFFFF">0.017</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">Neurologic disease</td>
<td align="justify" style="background-color:#FFFFFF">1.61</td>
<td align="justify" style="background-color:#FFFFFF">1.00 to 2.60</td>
<td align="justify" style="background-color:#FFFFFF">0.052</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">Diabetes mellitus</td>
<td align="justify" style="background-color:#FFFFFF">2.07</td>
<td align="justify" style="background-color:#FFFFFF">1.26 to 3.39</td>
<td align="justify" style="background-color:#FFFFFF">0.004</td>
<td align="justify" style="background-color:#FFFFFF">1.68</td>
<td align="justify" style="background-color:#FFFFFF">0.99 to 2.85</td>
<td align="justify" style="background-color:#FFFFFF">0.054</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">SOFA score ≥5<xref ref-type="table-fn" rid="t004fn005"><sup>d</sup></xref></td>
<td align="justify" style="background-color:#FFFFFF">7.22</td>
<td align="justify" style="background-color:#FFFFFF">4.70 to 11.08</td>
<td align="justify" style="background-color:#FFFFFF">&lt;0.001</td>
<td align="justify" style="background-color:#FFFFFF">3.91</td>
<td align="justify" style="background-color:#FFFFFF">2.17 to 7.03</td>
<td align="justify" style="background-color:#FFFFFF">&lt;0.001</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">Invasive pneumococcal pneumonia</td>
<td align="justify" style="background-color:#FFFFFF">1.63</td>
<td align="justify" style="background-color:#FFFFFF">1.04 to 2.55</td>
<td align="justify" style="background-color:#FFFFFF">0.034</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">Empiric antibiotic therapy<xref ref-type="table-fn" rid="t004fn006"><sup>e</sup></xref></td>
<td align="justify" style="background-color:#FFFFFF"/>
<td align="justify" style="background-color:#FFFFFF"/>
<td align="justify" style="background-color:#FFFFFF">0.001</td>
<td align="justify" style="background-color:#FFFFFF"/>
<td align="justify" style="background-color:#FFFFFF"/>
<td align="justify" style="background-color:#FFFFFF">0.11</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">  Beta-lactams monotherapy</td>
<td align="justify" style="background-color:#FFFFFF">1.14</td>
<td align="justify" style="background-color:#FFFFFF">0.49 to 2.63</td>
<td align="justify" style="background-color:#FFFFFF">0.76</td>
<td align="justify" style="background-color:#FFFFFF">1.08</td>
<td align="justify" style="background-color:#FFFFFF">0.44 to 2.63</td>
<td align="justify" style="background-color:#FFFFFF">0.87</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">  Fluoroquinolones monotherapy</td>
<td align="justify" style="background-color:#FFFFFF">0.51</td>
<td align="justify" style="background-color:#FFFFFF">0.22 to 1.19</td>
<td align="justify" style="background-color:#FFFFFF">0.12</td>
<td align="justify" style="background-color:#FFFFFF">1.52</td>
<td align="justify" style="background-color:#FFFFFF">0.59 to 3.94</td>
<td align="justify" style="background-color:#FFFFFF">0.38</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">  Beta-lactams plus fluoroquinolones</td>
<td align="justify" style="background-color:#FFFFFF">0.96</td>
<td align="justify" style="background-color:#FFFFFF">0.51 to 1.81</td>
<td align="justify" style="background-color:#FFFFFF">0.90</td>
<td align="justify" style="background-color:#FFFFFF">1.32</td>
<td align="justify" style="background-color:#FFFFFF">0.62 to 2.81</td>
<td align="justify" style="background-color:#FFFFFF">0.48</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">  Beta-lactams plus macrolides</td>
<td align="justify" style="background-color:#FFFFFF">0.35</td>
<td align="justify" style="background-color:#FFFFFF">0.18 to 0.68</td>
<td align="justify" style="background-color:#FFFFFF">0.002</td>
<td align="justify" style="background-color:#FFFFFF">0.59</td>
<td align="justify" style="background-color:#FFFFFF">0.29 to 1.21</td>
<td align="justify" style="background-color:#FFFFFF">0.15</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">  Other</td>
<td align="justify" style="background-color:#FFFFFF">1.00</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">1.00</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">Adequate empiric antibiotic therapy</td>
<td align="justify" style="background-color:#FFFFFF">0.22</td>
<td align="justify" style="background-color:#FFFFFF">0.11 to 0.45</td>
<td align="justify" style="background-color:#FFFFFF">&lt;0.001</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">ICU admission</td>
<td align="justify" style="background-color:#FFFFFF">5.17</td>
<td align="justify" style="background-color:#FFFFFF">3.31 to 8.02</td>
<td align="justify" style="background-color:#FFFFFF">&lt;0.001</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">Mechanical ventilation<xref ref-type="table-fn" rid="t004fn007"><sup>f</sup></xref></td>
<td align="justify" style="background-color:#FFFFFF"/>
<td align="justify" style="background-color:#FFFFFF"/>
<td align="justify" style="background-color:#FFFFFF">&lt;0.001</td>
<td align="justify" style="background-color:#FFFFFF"/>
<td align="justify" style="background-color:#FFFFFF"/>
<td align="justify" style="background-color:#FFFFFF">&lt;0.001</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">  Not ventilated</td>
<td align="justify" style="background-color:#FFFFFF">1.00</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">1.00</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
<td align="justify" style="background-color:#FFFFFF">–</td>
</tr>
<tr>
<td align="justify">  Non-invasive</td>
<td align="justify">5.86</td>
<td align="justify">2.69 to 12.78</td>
<td align="justify">&lt;0.001</td>
<td align="justify">2.95</td>
<td align="justify">1.22 to 7.16</td>
<td align="justify">0.017</td>
</tr>
<tr>
<td align="justify">  Invasive</td>
<td align="justify">8.85</td>
<td align="justify">5.58 to 14.02</td>
<td align="justify">&lt;0.001</td>
<td align="justify">4.07</td>
<td align="justify">2.40 to 6.88</td>
<td align="justify">&lt;0.001</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t004fn001"><p>Abbreviations: CI indicates confidence interval; HR, hazard ratio; ICU, intensive care unit; SOFA, sequential organ failure assessment. Data are shown as estimated HRs (95% CIs) of the explanatory variables in the 30-day mortality group. The HR is the ratio of hazards (probability of death) in two groups, given that the patient has survived up to a specific time. The P-value is based on the null hypothesis that all HRs relating to an explanatory variable equal unity (no effect).</p></fn>
<fn id="t004fn002"><p><sup>a</sup> The variables analyzed in the univariable analysis were: age, gender, tobacco use, alcohol consumption, influenza and pneumococcal vaccination, previous systemic and inhaled corticosteroids, prior antibiotic treatment, chronic pulmonary disease, chronic cardiovascular disease, chronic renal disease, chronic liver disease, diabetes mellitus, neurological disease, SOFA score, invasive disease pneumonia, adequate empiric antibiotic therapy, ICU admission, and mechanical ventilation.</p></fn>
<fn id="t004fn003"><p><sup>b</sup> Adjusted for the propensity score.</p></fn>
<fn id="t004fn004"><p><sup>c</sup> The p-value corresponds to differences between the four groups (1997–2001, 2002–2006, 2007–2011, or 2012–2016).</p></fn>
<fn id="t004fn005"><p><sup>d</sup> Optimal cut-off value to predict 30-day mortality using ROC curves.</p></fn>
<fn id="t004fn006"><p><sup>e</sup> The p-value corresponds to differences between the five groups (beta-lactams monotherapy, fluoroquinolones monotherapy, beta-lactams plus fluoroquinolones, beta-lactams plus macrolides, or other).</p></fn>
<fn id="t004fn007"><p><sup>f</sup> The p-value corresponds to differences between the three groups (not ventilated, non-invasive, or invasive).</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The AUC was 0.70 (95% CI, 0.64–0.76) for the model predictive of 30-day mortality (<xref ref-type="supplementary-material" rid="pone.0200504.s002">S2 Fig</xref>). The sensitivity was 63% (95% CI, 52%–74%), specificity was 68% (95% CI, 65%–71%), positive predictive value was 14% (95% CI, 10%–17%), negative predictive value was 96% (95% CI, 94%–97%), positive likelihood ratio was 1.97 (95% CI, 1.64–2.38), and negative likelihood ratio was 0.54 (95% CI, 0.41–0.72). Internal validation of the Cox regression model by bootstrapping demonstrated robust results for all variables included in the model, with small 95% CIs around the original coefficients (<xref ref-type="supplementary-material" rid="pone.0200504.s004">S1 Table</xref>).</p>
<p>The univariable Cox regression analysis revealed several variables significantly associated with ICU mortality among the subset of patients admitted to the ICU “<xref ref-type="table" rid="pone.0200504.t005">Table 5</xref>”. Notably, age ≥65 years and requirement for invasive mechanical ventilation were independently associated with ICU mortality in the propensity-adjusted multivariable analysis. Again, however, period of admission was not significantly associated with ICU mortality after adjustment for potential confounders. The AUC was 0.70 (95% CI, 0.62–0.78) for the model predictive of ICU mortality (<xref ref-type="supplementary-material" rid="pone.0200504.s003">S3 Fig</xref>). The sensitivity was 85% (95% CI, 73%–97%), specificity was 49% (95% CI, 43%–55%), positive predictive value was 21% (95% CI, 14%–27%), negative predictive value was 96% (95% CI, 92%–99%), positive likelihood ratio was 1.67 (95% CI, 1.40–1.99), and negative likelihood ratio was 0.30 (95% CI, 0.14–0.63). Internal validation of the Cox regression model by bootstrapping demonstrated robust results for all the variables included in the model, with small 95% CIs around the original coefficients (<xref ref-type="supplementary-material" rid="pone.0200504.s005">S2 Table</xref>).</p>
<table-wrap id="pone.0200504.t005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0200504.t005</object-id>
<label>Table 5</label> <caption><title>Significant univariable and multivariable cox regression analyses for the prediction of icu mortality.</title></caption>
<alternatives>
<graphic id="pone.0200504.t005g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0200504.t005" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="justify" rowspan="2" style="background-color:#FFFFFF">Variable</th>
<th align="justify" colspan="3" style="background-color:#FFFFFF">Univariable<xref ref-type="table-fn" rid="t005fn002"><sup>a</sup></xref></th>
<th align="justify" colspan="3" style="background-color:#FFFFFF">Multivariable<xref ref-type="table-fn" rid="t005fn003"><sup>b</sup></xref></th>
</tr>
<tr>
<th align="justify">HR</th>
<th align="justify">95% CI</th>
<th align="justify">P-value</th>
<th align="justify">HR</th>
<th align="justify">95% CI</th>
<th align="justify">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="justify">Period of admission<xref ref-type="table-fn" rid="t005fn004"><sup>c</sup></xref></td>
<td align="justify"/>
<td align="justify"/>
<td align="justify">0.10</td>
<td align="justify"/>
<td align="justify"/>
<td align="justify">0.38</td>
</tr>
<tr>
<td align="justify">  1997–2001</td>
<td align="justify">1.00</td>
<td align="justify">–</td>
<td align="justify">–</td>
<td align="justify">1.00</td>
<td align="justify">–</td>
<td align="justify">–</td>
</tr>
<tr>
<td align="justify">  2002–2006</td>
<td align="justify">0.36</td>
<td align="justify">0.15 to 0.85</td>
<td align="justify">0.020</td>
<td align="justify">2.72</td>
<td align="justify">0.04 to 211.36</td>
<td align="justify">0.65</td>
</tr>
<tr>
<td align="justify">  2007–2011</td>
<td align="justify">0.54</td>
<td align="justify">0.25 to 1.19</td>
<td align="justify">0.13</td>
<td align="justify">7.56</td>
<td align="justify">0.03 to 1,688.48</td>
<td align="justify">0.46</td>
</tr>
<tr>
<td align="justify">  2012–2016</td>
<td align="justify">0.50</td>
<td align="justify">0.20 to 1.23</td>
<td align="justify">0.13</td>
<td align="justify">1.96</td>
<td align="justify">0.06 to 67.07</td>
<td align="justify">0.71</td>
</tr>
<tr>
<td align="justify">Age ≥65 years</td>
<td align="justify">2.34</td>
<td align="justify">1.17 to 4.67</td>
<td align="justify">0.016</td>
<td align="justify">2.27</td>
<td align="justify">1.08 to 4.79</td>
<td align="justify">0.031</td>
</tr>
<tr>
<td align="justify">SOFA score ≥5<xref ref-type="table-fn" rid="t005fn005"><sup>d</sup></xref></td>
<td align="justify">2.68</td>
<td align="justify">1.40 to 5.13</td>
<td align="justify">0.003</td>
<td align="justify">–</td>
<td align="justify">–</td>
<td align="justify">–</td>
</tr>
<tr>
<td align="justify">Empiric antibiotic therapy<xref ref-type="table-fn" rid="t005fn006"><sup>e</sup></xref></td>
<td align="justify"/>
<td align="justify"/>
<td align="justify">0.21</td>
<td align="justify"/>
<td align="justify"/>
<td align="justify">0.29</td>
</tr>
<tr>
<td align="justify">  Beta-lactams monotherapy</td>
<td align="justify">1.66</td>
<td align="justify">0.45 to 6.14</td>
<td align="justify">0.45</td>
<td align="justify">0.75</td>
<td align="justify">0.18 to 3.04</td>
<td align="justify">0.68</td>
</tr>
<tr>
<td align="justify">  Fluoroquinolones monotherapy</td>
<td align="justify">1.13</td>
<td align="justify">0.31 to 4.19</td>
<td align="justify">0.85</td>
<td align="justify">2.84</td>
<td align="justify">0.63 to 12.76</td>
<td align="justify">0.17</td>
</tr>
<tr>
<td align="justify">  Beta-lactams plus fluoroquinolones</td>
<td align="justify">0.58</td>
<td align="justify">0.25 to 1.35</td>
<td align="justify">0.21</td>
<td align="justify">0.98</td>
<td align="justify">0.33 to 2.90</td>
<td align="justify">0.97</td>
</tr>
<tr>
<td align="justify">  Beta-lactams plus macrolides</td>
<td align="justify">0.50</td>
<td align="justify">0.21 to 1.19</td>
<td align="justify">0.12</td>
<td align="justify">0.58</td>
<td align="justify">0.23 to 1.42</td>
<td align="justify">0.23</td>
</tr>
<tr>
<td align="justify">  Other</td>
<td align="justify">1.00</td>
<td align="justify">–</td>
<td align="justify">–</td>
<td align="justify">1.00</td>
<td align="justify">–</td>
<td align="justify">–</td>
</tr>
<tr>
<td align="justify">Adequate empiric antibiotic therapy</td>
<td align="justify">0.37</td>
<td align="justify">0.17 to 0.79</td>
<td align="justify">0.011</td>
<td align="justify">–</td>
<td align="justify">–</td>
<td align="justify">–</td>
</tr>
<tr>
<td align="justify">Mechanical ventilation<xref ref-type="table-fn" rid="t005fn007"><sup>f</sup></xref></td>
<td align="justify"/>
<td align="justify"/>
<td align="justify">0.001</td>
<td align="justify"/>
<td align="justify"/>
<td align="justify">0.017</td>
</tr>
<tr>
<td align="justify">  Not ventilated</td>
<td align="justify">1.00</td>
<td align="justify">–</td>
<td align="justify">–</td>
<td align="justify">1.00</td>
<td align="justify">–</td>
<td align="justify">–</td>
</tr>
<tr>
<td align="justify">  Non-invasive</td>
<td align="justify">2.07</td>
<td align="justify">0.58 to 7.33</td>
<td align="justify">0.26</td>
<td align="justify">2.21</td>
<td align="justify">0.60 to 8.23</td>
<td align="justify">0.24</td>
</tr>
<tr>
<td align="justify">  Invasive</td>
<td align="justify">4.97</td>
<td align="justify">2.04 to 12.08</td>
<td align="justify">&lt;0.001</td>
<td align="justify">3.76</td>
<td align="justify">1.51 to 9.37</td>
<td align="justify">0.005</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t005fn001"><p>Abbreviations: CI indicates confidence interval; HR, hazard ratio; ICU, intensive care unit; SOFA, sequential organ failure assessment. Data are shown as estimated HRs (95% CIs) of the explanatory variables in the ICU mortality group. The HR is the ratio of hazards (probability of death) in two groups, given that the patient has survived up to a specific time. The P-value is based on the null hypothesis that all HRs relating to an explanatory variable equal unity (no effect).</p></fn>
<fn id="t005fn002"><p><sup>a</sup> The variables analyzed in the univariable analysis were: age, gender, tobacco use, alcohol consumption, influenza and pneumococcal vaccination, previous systemic and inhaled corticosteroids, prior antibiotic treatment, chronic pulmonary disease, chronic cardiovascular disease, chronic renal disease, chronic liver disease, diabetes mellitus, neurological disease, SOFA score, invasive disease pneumonia, adequate empiric antibiotic therapy, and mechanical ventilation.</p></fn>
<fn id="t005fn003"><p><sup>b</sup> Adjusted for the propensity score.</p></fn>
<fn id="t005fn004"><p><sup>c</sup> The p-value corresponds to differences between the four groups (1997–2001, 2002–2006, 2007–2011, or 2012–2016).</p></fn>
<fn id="t005fn005"><p><sup>d</sup> Optimal cut-off value to predict 30-day mortality using ROC curves.</p></fn>
<fn id="t005fn006"><p><sup>e</sup> The p-value corresponds to differences between the five groups (beta-lactams monotherapy, fluoroquinolones monotherapy, beta-lactams plus fluoroquinolones, beta-lactams plus macrolides, or other).</p></fn>
<fn id="t005fn007"><p><sup>f</sup> The p-value corresponds to differences between the three groups (not ventilated, non-invasive, or invasive).</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="sec017" sec-type="conclusions">
<title>Discussion</title>
<p>There are three main findings to this study. First, it was striking that the 30-day mortality of patients hospitalized for pneumococcal CAP did not change significantly over time (this included early and late mortality). Second, although we observed a progressive increase in the number of patients admitted to ICU and receiving NIV between periods, the mortality of patients receiving NIV in ICU did not change over that time. Third, mortality in ICU fell from 26% in the first study period to 10% in the second period, and remained stable thereafter; however, when we adjusted by propensity-adjusted multivariable analysis, study period was not associated with higher mortality.</p>
<p>Recently, there have been few studies about the changes in CAP-related mortality over time[<xref ref-type="bibr" rid="pone.0200504.ref005">5</xref>,<xref ref-type="bibr" rid="pone.0200504.ref006">6</xref>,<xref ref-type="bibr" rid="pone.0200504.ref037">37</xref>], with only limited information about the 30-day mortality in patients hospitalized with pneumococcal CAP over study periods of a decade or longer[<xref ref-type="bibr" rid="pone.0200504.ref024">24</xref>].</p>
<p>This study is the first, to our knowledge, to describe trends in 30-day mortality over a 20 year period in patients hospitalized with confirmed pneumococcal CAP. It was remarkable that we found no evidence of 30-day mortality for pneumococcal CAP decreasing in hospitalized adult patients over that period. Nevertheless, our results are consistent with those of epidemiological research in Canada (excluding Quebec) over a 6 year period[<xref ref-type="bibr" rid="pone.0200504.ref024">24</xref>]. In that study, the authors reported that case-fatality rates from pneumococcal pneumonia remained stable (11.6% to 12.3%) between 2004 and 2010, although they did report a decrease in the incidence of CAP due to <italic>S</italic>. <italic>pneumoniae</italic>, which they attributed to vaccination programs. However, they relied entirely on retrospective data extracted from an administrative database, which would be subject to potential biases, especially in the case of <italic>S</italic>. <italic>pneumoniae</italic> diagnosis. By contrast, our data acquisition was prospective and relied on a confirmed microbiological diagnosis of <italic>S</italic>. <italic>pneumoniae</italic>. In addition, our 30-day mortality was 3%–4% lower than that reported by the Canadian group.</p>
<p>Although we did not observe a fall in 30-day mortality over time, an interesting finding was the decrease in the presence of comorbidities, and also the decrease in the proportion of current smokers over time. One possible explanation is the change of pneumococcal serotypes over the course of the study period. Since the beginning of 2000, serotype evolution in pneumococcus has been in constant progress, influenced by the introduction of pneumococcal conjugate vaccines (PCVs)[<xref ref-type="bibr" rid="pone.0200504.ref021">21</xref>,<xref ref-type="bibr" rid="pone.0200504.ref038">38</xref>]. Despite the effectiveness of the PCV in reducing the burden of invasive pneumococcal disease, the incidence of complicated pneumonia[<xref ref-type="bibr" rid="pone.0200504.ref039">39</xref>] is rising because of the emergence of non-vaccine serotypes. This increase does not appear to be related to the concurrent increase in penicillin-resistant <italic>S</italic>. <italic>pneumoniae</italic> but does seem related to the introduction of virulent clones expressing non-vaccine serotypes, especially serotype 1[<xref ref-type="bibr" rid="pone.0200504.ref040">40</xref>]. On the other hand, we cannot rule out the possible effect of ambient air pollution on on the incidence of pneumococcal infections[<xref ref-type="bibr" rid="pone.0200504.ref041">41</xref>–<xref ref-type="bibr" rid="pone.0200504.ref043">43</xref>] as reported by a Spanish study of 619 cases of pneumococcal infections which found that fossil fuel-derived pollutants (SO<sub>2</sub>, NO), and dry and cold air increased the incidence of pneumococcal infections[<xref ref-type="bibr" rid="pone.0200504.ref043">43</xref>].</p>
<p>We observed an increase in patients admitted to ICU, as well increases in the proportions of patient with ARDS, with septic shock, and requiring NIV. These data are consistent with results of a UK study in which it was reported that a growing number of CAP cases have required ICU admission in the last 20 years, regardless of age groups[<xref ref-type="bibr" rid="pone.0200504.ref044">44</xref>]. The reason for the increase in ICU admission is probably related to a better knowledge among clinicians of the definitions of severe CAP in international guidelines[<xref ref-type="bibr" rid="pone.0200504.ref011">11</xref>,<xref ref-type="bibr" rid="pone.0200504.ref045">45</xref>].</p>
<p>ICU mortality was 26% in the first period, dropped to 10% in the second period, and then remained stable. However, we could not confirm this downward trend and subsequent stabilization when adjusting the results by propensity-adjusted multivariable analysis. We think that the reduction in ICU mortality between the first and the second periods of our study was related to the 2001 and 2007 CAP guidelines[<xref ref-type="bibr" rid="pone.0200504.ref010">10</xref>,<xref ref-type="bibr" rid="pone.0200504.ref011">11</xref>], recommendations from the Surviving Sepsis campaign[<xref ref-type="bibr" rid="pone.0200504.ref029">29</xref>], and the implementation of early initiation of the first antibiotic dose[<xref ref-type="bibr" rid="pone.0200504.ref046">46</xref>]. There are two previous studies, one in hospitalized CAP[<xref ref-type="bibr" rid="pone.0200504.ref012">12</xref>] and another one in severe CAP[<xref ref-type="bibr" rid="pone.0200504.ref013">13</xref>], that have demonstrated reductions in mortality after guideline implementation.</p>
<p>It is noteworthy that our data are in partial disagreement with the results of Gattarello et al.[<xref ref-type="bibr" rid="pone.0200504.ref037">37</xref>], who conducted a matched case-control study (80 cases and 80 controls) comparing the periods 2000–2002 and 2008–2013. They reported a 15% decrease in mortality among patients with pneumococcal pneumonia admitted to the ICU, and that early antibiotic administration and combination antibiotic therapy were independently associated with better outcomes. However, there were important differences with our study: (a) we included the data for 1,120 patients and the study by Gattarello et al.[<xref ref-type="bibr" rid="pone.0200504.ref037">37</xref>] included only 160 patients; (b) more than 60% of the patients (n = 701) were aged ≥65 years in our cohort, whereas only 33% (n = 54) were aged ≥65 years in their cohort; and c) antibiotic therapy did not affect mortality in our study because most patients received adequate empirical antibiotic therapy.</p>
<p>The major strengths of our study are the large cohort, long study period, consecutive enrollment, and inclusion of only cases with microbiologically confirmed pneumococcal CAP. However, a potential limitation of the study is that data were collected from a single academic teaching hospital in Spain, which has extensive experience in the management of CAP; consequently, it may not be possible to extrapolate our results to patients admitted to other types of hospitals in other countries. Other potential limitations are the changes in the diagnosis, treatment, and prevention of CAP during the 20 years of study for which we did not account. However, our antibiotic treatment protocol has not changed substantially for CAP during these years, and we have followed the 1993, 1998, 2001, and 2007 guidelines for managing CAP[<xref ref-type="bibr" rid="pone.0200504.ref008">8</xref>–<xref ref-type="bibr" rid="pone.0200504.ref011">11</xref>].</p>
<p>In conclusion, we observed increases in the rates of patients admitted to ICU and in the rates of ARDS, septic shock, and requirement for NIV. We did not find a decrease in mortality from pneumococcal CAP. Given that mortality from pneumococcal pneumonia has not changed for many years despite treatment with appropriate antimicrobial therapy, there is a growing need for non-antibiotic strategies to be investigated.</p>
</sec>
<sec id="sec018">
<title>Supporting information</title>
<supplementary-material id="pone.0200504.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0200504.s001" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Kaplan–Meier analysis of the effect of period on time to death in intensive care.</title>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0200504.s002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0200504.s002" xlink:type="simple">
<label>S2 Fig</label>
<caption>
<title>ROC Analysis of significant variables derived from the logistic regression model to predict 30-day mortality.</title>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0200504.s003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0200504.s003" xlink:type="simple">
<label>S3 Fig</label>
<caption>
<title>ROC analysis of significant variables derived from the logistic regression model to predict ICU mortality.</title>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0200504.s004" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0200504.s004" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Internal validation of the prediction model for 30-Day mortality by the nonparametric bootstrap technique.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0200504.s005" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0200504.s005" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>Internal validation of the prediction model for ICU mortality by the nonparametric bootstrap technique.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>The results presented have not been published elsewhere. We are indebted to all medical and nursing colleagues for their assistance and cooperation in this study.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0200504.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Welte</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Torres</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Nathwani</surname> <given-names>D</given-names></name>. <article-title>Clinical and economic burden of community-acquired pneumonia among adults in Europe</article-title>. <source>Thorax</source>. <year>2012</year> <month>Jan</month>;<volume>67</volume>(<issue>1</issue>):<fpage>71</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/thx.2009.129502" xlink:type="simple">10.1136/thx.2009.129502</ext-link></comment> <object-id pub-id-type="pmid">20729232</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><collab>GBD 2015 Mortality and Causes of Death Collaborators</collab>. <article-title>Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015</article-title>. <source>Lancet Lond Engl</source>. <year>2016</year> <month>Oct</month> <day>8</day>;<volume>388</volume>(<issue>10053</issue>):<fpage>1459</fpage>–<lpage>544</lpage>.</mixed-citation></ref>
<ref id="pone.0200504.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>López-de-Andrés</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>de Miguel-Díez</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Jiménez-Trujillo</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Hernández-Barrera</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>de Miguel-Yanes</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Méndez-Bailón</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Hospitalisation with community-acquired pneumonia among patients with type 2 diabetes: an observational population-based study in Spain from 2004 to 2013</article-title>. <source>BMJ Open</source>. <year>2017</year> <month>Jan</month> <day>5</day>;<volume>7</volume>(<issue>1</issue>):<fpage>e013097</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmjopen-2016-013097" xlink:type="simple">10.1136/bmjopen-2016-013097</ext-link></comment> <object-id pub-id-type="pmid">28057653</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>de Miguel-Díez</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Jiménez-García</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Hernández-Barrera</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Jiménez-Trujillo</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>de Miguel-Yanes</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Méndez-Bailón</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Trends in hospitalizations for community-acquired pneumonia in Spain: 2004 to 2013</article-title>. <source>Eur J Intern Med</source>. <year>2017</year> <month>May</month>;<volume>40</volume>:<fpage>64</fpage>–<lpage>71</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ejim.2016.12.010" xlink:type="simple">10.1016/j.ejim.2016.12.010</ext-link></comment> <object-id pub-id-type="pmid">27979670</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Simonetti</surname> <given-names>AF</given-names></name>, <name name-style="western"><surname>Garcia-Vidal</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Viasus</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>García-Somoza</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Dorca</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Gudiol</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Declining mortality among hospitalized patients with community-acquired pneumonia</article-title>. <source>Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis</source>. <year>2016</year> <month>Jun</month>;<volume>22</volume>(<issue>6</issue>):<fpage>567.e1</fpage>–<lpage>7</lpage>.</mixed-citation></ref>
<ref id="pone.0200504.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ruhnke</surname> <given-names>GW</given-names></name>, <name name-style="western"><surname>Coca-Perraillon</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kitch</surname> <given-names>BT</given-names></name>, <name name-style="western"><surname>Cutler</surname> <given-names>DM</given-names></name>. <article-title>Trends in mortality and medical spending in patients hospitalized for community-acquired pneumonia: 1993–2005</article-title>. <source>Med Care</source>. <year>2010</year> <month>Dec</month>;<volume>48</volume>(<issue>12</issue>):<fpage>1111</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/MLR.0b013e3181f38006" xlink:type="simple">10.1097/MLR.0b013e3181f38006</ext-link></comment> <object-id pub-id-type="pmid">21063230</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Daniel</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Woodhead</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Welham</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mckeever</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Lim</surname> <given-names>WS</given-names></name>, <collab>British Thoracic Society</collab>. <article-title>Mortality reduction in adult community-acquired pneumonia in the UK (2009–2014): results from the British Thoracic Society audit programme</article-title>. <source>Thorax</source>. <year>2016</year> <month>Nov</month>;<volume>71</volume>(<issue>11</issue>):<fpage>1061</fpage>–<lpage>3</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/thoraxjnl-2016-208937" xlink:type="simple">10.1136/thoraxjnl-2016-208937</ext-link></comment> <object-id pub-id-type="pmid">27534681</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Niederman</surname> <given-names>MS</given-names></name>, <name name-style="western"><surname>Bass</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Campbell</surname> <given-names>GD</given-names></name>, <name name-style="western"><surname>Fein</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Grossman</surname> <given-names>RF</given-names></name>, <name name-style="western"><surname>Mandell</surname> <given-names>LA</given-names></name>, <etal>et al</etal>. <article-title>Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association</article-title>. <source>Am Rev Respir Dis</source>. <year>1993</year> <month>Nov</month>;<volume>148</volume>(<issue>5</issue>):<fpage>1418</fpage>–<lpage>26</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1164/ajrccm/148.5.1418" xlink:type="simple">10.1164/ajrccm/148.5.1418</ext-link></comment> <object-id pub-id-type="pmid">8239186</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bartlett</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Breiman</surname> <given-names>RF</given-names></name>, <name name-style="western"><surname>Mandell</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>File</surname> <given-names>TM</given-names></name>. <article-title>Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America</article-title>. <source>Clin Infect Dis Off Publ Infect Dis Soc Am</source>. <year>1998</year> <month>Apr</month>;<volume>26</volume>(<issue>4</issue>):<fpage>811</fpage>–<lpage>38</lpage>.</mixed-citation></ref>
<ref id="pone.0200504.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Niederman</surname> <given-names>MS</given-names></name>, <name name-style="western"><surname>Mandell</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Anzueto</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bass</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Broughton</surname> <given-names>WA</given-names></name>, <name name-style="western"><surname>Campbell</surname> <given-names>GD</given-names></name>, <etal>et al</etal>. <article-title>Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2001</year> <month>Jun</month>;<volume>163</volume>(<issue>7</issue>):<fpage>1730</fpage>–<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1164/ajrccm.163.7.at1010" xlink:type="simple">10.1164/ajrccm.163.7.at1010</ext-link></comment> <object-id pub-id-type="pmid">11401897</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mandell</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Wunderink</surname> <given-names>RG</given-names></name>, <name name-style="western"><surname>Anzueto</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bartlett</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Campbell</surname> <given-names>GD</given-names></name>, <name name-style="western"><surname>Dean</surname> <given-names>NC</given-names></name>, <etal>et al</etal>. <article-title>Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults</article-title>. <source>Clin Infect Dis Off Publ Infect Dis Soc Am</source>. <year>2007</year> <month>Mar</month> <day>1</day>;<volume>44</volume> <issue>Suppl 2</issue>:<fpage>S27</fpage>–<lpage>72</lpage>.</mixed-citation></ref>
<ref id="pone.0200504.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dean</surname> <given-names>NC</given-names></name>, <name name-style="western"><surname>Silver</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Bateman</surname> <given-names>KA</given-names></name>, <name name-style="western"><surname>James</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Hadlock</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Hale</surname> <given-names>D</given-names></name>. <article-title>Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia</article-title>. <source>Am J Med</source>. <year>2001</year> <month>Apr</month> <day>15</day>;<volume>110</volume>(<issue>6</issue>):<fpage>451</fpage>–<lpage>7</lpage>. <object-id pub-id-type="pmid">11331056</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Georges</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Journaux</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Devos</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Alfandari</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Delannoy</surname> <given-names>PY</given-names></name>, <name name-style="western"><surname>Meybeck</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Improvement in process of care and outcome in patients requiring intensive care unit admission for community acquired pneumonia</article-title>. <source>BMC Infect Dis</source>. <year>2013</year> <month>Apr</month> <day>30</day>;<volume>13</volume>:<fpage>196</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2334-13-196" xlink:type="simple">10.1186/1471-2334-13-196</ext-link></comment> <object-id pub-id-type="pmid">23631630</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kaukonen</surname> <given-names>K-M</given-names></name>, <name name-style="western"><surname>Bailey</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Suzuki</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Pilcher</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Bellomo</surname> <given-names>R</given-names></name>. <article-title>Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012</article-title>. <source>JAMA</source>. <year>2014</year> <month>Apr</month> <day>2</day>;<volume>311</volume>(<issue>13</issue>):<fpage>1308</fpage>–<lpage>16</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jama.2014.2637" xlink:type="simple">10.1001/jama.2014.2637</ext-link></comment> <object-id pub-id-type="pmid">24638143</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ma</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ward</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Siegel</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Jemal</surname> <given-names>A</given-names></name>. <article-title>Temporal Trends in Mortality in the United States, 1969–2013</article-title>. <source>JAMA</source>. <year>2015</year> <month>Oct</month> <day>27</day>;<volume>314</volume>(<issue>16</issue>):<fpage>1731</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jama.2015.12319" xlink:type="simple">10.1001/jama.2015.12319</ext-link></comment> <object-id pub-id-type="pmid">26505597</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cilloniz</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Ewig</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Gabarrus</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ferrer</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Puig de la Bella Casa</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Mensa</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Seasonality of pathogens causing community-acquired pneumonia</article-title>. <source>Respirol Carlton Vic</source>. <year>2017</year> <month>Jan</month> <day>17</day>;</mixed-citation></ref>
<ref id="pone.0200504.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cillóniz</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Ewig</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Polverino</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Marcos</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Esquinas</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Gabarrús</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Microbial aetiology of community-acquired pneumonia and its relation to severity</article-title>. <source>Thorax</source>. <year>2011</year> <month>Apr</month>;<volume>66</volume>(<issue>4</issue>):<fpage>340</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/thx.2010.143982" xlink:type="simple">10.1136/thx.2010.143982</ext-link></comment> <object-id pub-id-type="pmid">21257985</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pletz</surname> <given-names>MW</given-names></name>, <name name-style="western"><surname>von Baum</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>van der Linden</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Rohde</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Schütte</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Suttorp</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>The burden of pneumococcal pneumonia—experience of the German competence network CAPNETZ</article-title>. <source>Pneumol Stuttg Ger</source>. <year>2012</year> <month>Aug</month>;<volume>66</volume>(<issue>8</issue>):<fpage>470</fpage>–<lpage>5</lpage>.</mixed-citation></ref>
<ref id="pone.0200504.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vila-Corcoles</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ochoa-Gondar</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Hospital</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>de Diego</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Satué</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Bladé</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia</article-title>. <source>Hum Vaccines Immunother</source>. <year>2016</year>;<volume>12</volume>(<issue>11</issue>):<fpage>2953</fpage>–<lpage>8</lpage>.</mixed-citation></ref>
<ref id="pone.0200504.ref020"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Prevenció de la malaltia pneumocòccica en els adults i en els infants a partir dels 5 anys a Catalunya [Internet]. 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://canalsalut.gencat.cat/web/.content/home_canal_salut/professionals/temes_de_salut/vacunacions/documents/arxius/prevencio_neumo_catalunya_adults.pdf" xlink:type="simple">http://canalsalut.gencat.cat/web/.content/home_canal_salut/professionals/temes_de_salut/vacunacions/documents/arxius/prevencio_neumo_catalunya_adults.pdf</ext-link></mixed-citation></ref>
<ref id="pone.0200504.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Muñoz-Almagro</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Jordan</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Gene</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Latorre</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Garcia-Garcia</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Pallares</surname> <given-names>R</given-names></name>. <article-title>Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine</article-title>. <source>Clin Infect Dis Off Publ Infect Dis Soc Am</source>. <year>2008</year> <month>Jan</month> <day>15</day>;<volume>46</volume>(<issue>2</issue>):<fpage>174</fpage>–<lpage>82</lpage>.</mixed-citation></ref>
<ref id="pone.0200504.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moraga-Llop</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Garcia-Garcia</surname> <given-names>J-J</given-names></name>, <name name-style="western"><surname>Díaz-Conradi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ciruela</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Martínez-Osorio</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>González-Peris</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Vaccine Failures in Patients Properly Vaccinated with 13-Valent Pneumococcal Conjugate Vaccine in Catalonia, a Region with Low Vaccination Coverage</article-title>. <source>Pediatr Infect Dis J</source>. <year>2016</year> <month>Apr</month>;<volume>35</volume>(<issue>4</issue>):<fpage>460</fpage>–<lpage>3</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/INF.0000000000001041" xlink:type="simple">10.1097/INF.0000000000001041</ext-link></comment> <object-id pub-id-type="pmid">26658626</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vila-Corcoles</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ochoa-Gondar</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>de Diego</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Satue</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Aragón</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Vila-Rovira</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study</article-title>. <source>BMC Infect Dis</source>. <year>2018</year> <month>Apr</month> <day>27</day>;<volume>18</volume>(<issue>1</issue>):<fpage>196</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12879-018-3096-7" xlink:type="simple">10.1186/s12879-018-3096-7</ext-link></comment> <object-id pub-id-type="pmid">29699550</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mongardon</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Max</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bouglé</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Pène</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Lemiale</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Charpentier</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study</article-title>. <source>Crit Care</source>. <year>2012</year>;<volume>16</volume>:<fpage>R155</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/cc11471" xlink:type="simple">10.1186/cc11471</ext-link></comment> <object-id pub-id-type="pmid">22894879</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vincent</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Moreno</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Takala</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Willatts</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>De Mendonça</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bruining</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine</article-title>. <source>Intensive Care Med</source>. <year>1996</year> <month>Jul</month>;<volume>22</volume>(<issue>7</issue>):<fpage>707</fpage>–<lpage>10</lpage>. <object-id pub-id-type="pmid">8844239</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fine</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Auble</surname> <given-names>TE</given-names></name>, <name name-style="western"><surname>Yealy</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Hanusa</surname> <given-names>BH</given-names></name>, <name name-style="western"><surname>Weissfeld</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Singer</surname> <given-names>DE</given-names></name>, <etal>et al</etal>. <article-title>A prediction rule to identify low-risk patients with community-acquired pneumonia</article-title>. <source>N Engl J Med</source>. <year>1997</year> <month>Jan</month> <day>23</day>;<volume>336</volume>(<issue>4</issue>):<fpage>243</fpage>–<lpage>50</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJM199701233360402" xlink:type="simple">10.1056/NEJM199701233360402</ext-link></comment> <object-id pub-id-type="pmid">8995086</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lim</surname> <given-names>WS</given-names></name>, <name name-style="western"><surname>van der Eerden</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Laing</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Boersma</surname> <given-names>WG</given-names></name>, <name name-style="western"><surname>Karalus</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Town</surname> <given-names>GI</given-names></name>, <etal>et al</etal>. <article-title>Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study</article-title>. <source>Thorax</source>. <year>2003</year> <month>May</month>;<volume>58</volume>(<issue>5</issue>):<fpage>377</fpage>–<lpage>82</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/thorax.58.5.377" xlink:type="simple">10.1136/thorax.58.5.377</ext-link></comment> <object-id pub-id-type="pmid">12728155</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><collab>ARDS Definition Task Force</collab>, <name name-style="western"><surname>Ranieri</surname> <given-names>VM</given-names></name>, <name name-style="western"><surname>Rubenfeld</surname> <given-names>GD</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>BT</given-names></name>, <name name-style="western"><surname>Ferguson</surname> <given-names>ND</given-names></name>, <name name-style="western"><surname>Caldwell</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Acute respiratory distress syndrome: the Berlin Definition</article-title>. <source>JAMA</source>. <year>2012</year> <month>Jun</month> <day>20</day>;<volume>307</volume>(<issue>23</issue>):<fpage>2526</fpage>–<lpage>33</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jama.2012.5669" xlink:type="simple">10.1001/jama.2012.5669</ext-link></comment> <object-id pub-id-type="pmid">22797452</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dellinger</surname> <given-names>RP</given-names></name>, <name name-style="western"><surname>Carlet</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Masur</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Gerlach</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Calandra</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Cohen</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock</article-title>. <source>Intensive Care Med</source>. <year>2004</year> <month>Apr</month>;<volume>30</volume>(<issue>4</issue>):<fpage>536</fpage>–<lpage>55</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00134-004-2210-z" xlink:type="simple">10.1007/s00134-004-2210-z</ext-link></comment> <object-id pub-id-type="pmid">14997291</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref030"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care Lond Engl. 2004 Aug;8(4):R204-212.</mixed-citation></ref>
<ref id="pone.0200504.ref031"><label>31</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>DAVID</surname> <given-names>MOORE</given-names></name>, <name name-style="western"><surname>CABE</surname> <given-names>GEORGE MC</given-names></name>,<name name-style="western"><surname>BRUCE</surname> <given-names>CRAIG</given-names></name>. <chapter-title>Introduction to the practice of statistics</chapter-title>. <edition>8TH ed.</edition> <publisher-loc>New York</publisher-loc>: <publisher-name>W.H. Freeman and Company</publisher-name>;</mixed-citation></ref>
<ref id="pone.0200504.ref032"><label>32</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Van Houwelingen</surname> <given-names>H</given-names></name>. <source>Modelling Survival Data in Medical Research</source>. <name name-style="western"><surname>Collett</surname> <given-names>D.</given-names></name>, <publisher-name>Chapman &amp; Hall</publisher-name>, <publisher-loc>London</publisher-loc>, <year>1994</year>. No of pages: <fpage>XVII</fpage> + <lpage>347</lpage>. Price: E19.99. ISBN 0–41 2-44890-4. Stat Med. 1995 May 15;14(9):1147–8.</mixed-citation></ref>
<ref id="pone.0200504.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rosenbaum</surname> <given-names>PR</given-names></name>, <name name-style="western"><surname>Rubin</surname> <given-names>DB</given-names></name>. <article-title>The central role of the propensity score in observational studies for causal effects</article-title>. <source>Biometrika</source>. <year>1983</year> <month>Apr</month> <day>1</day>;<volume>70</volume>(<issue>1</issue>):<fpage>41</fpage>–<lpage>55</lpage>.</mixed-citation></ref>
<ref id="pone.0200504.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Psaty</surname> <given-names>BM</given-names></name>, <name name-style="western"><surname>Siscovick</surname> <given-names>DS</given-names></name>. <article-title>Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction</article-title>. <source>JAMA</source>. <year>2010</year> <month>Aug</month> <day>25</day>;<volume>304</volume>(<issue>8</issue>):<fpage>897</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jama.2010.1205" xlink:type="simple">10.1001/jama.2010.1205</ext-link></comment> <object-id pub-id-type="pmid">20736474</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref035"><label>35</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Efron</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Tibshirani</surname> <given-names>RJ</given-names></name>. <chapter-title>An Introduction to the Bootstrap</chapter-title>. <publisher-name>CRC Press</publisher-name>; <year>1994</year>. 456 p.</mixed-citation></ref>
<ref id="pone.0200504.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sterne</surname> <given-names>JAC</given-names></name>, <name name-style="western"><surname>White</surname> <given-names>IR</given-names></name>, <name name-style="western"><surname>Carlin</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Spratt</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Royston</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Kenward</surname> <given-names>MG</given-names></name>, <etal>et al</etal>. <article-title>Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls</article-title>. <source>BMJ</source>. <year>2009</year> <month>Jun</month> <day>29</day>;<volume>338</volume>:<fpage>b2393</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.b2393" xlink:type="simple">10.1136/bmj.b2393</ext-link></comment> <object-id pub-id-type="pmid">19564179</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gattarello</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Borgatta</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Solé-Violán</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Vallés</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Vidaur</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Zaragoza</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000–2013)</article-title>. <source>Chest</source>. <year>2014</year> <month>Jul</month>;<volume>146</volume>(<issue>1</issue>):<fpage>22</fpage>–<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1378/chest.13-1531" xlink:type="simple">10.1378/chest.13-1531</ext-link></comment> <object-id pub-id-type="pmid">24371840</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tin Tin Htar</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Christopoulou</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Schmitt</surname> <given-names>H-J</given-names></name>. <article-title>Pneumococcal serotype evolution in Western Europe</article-title>. <source>BMC Infect Dis</source>. <year>2015</year> <month>Oct</month> <day>14</day>;<volume>15</volume>:<fpage>419</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12879-015-1147-x" xlink:type="simple">10.1186/s12879-015-1147-x</ext-link></comment> <object-id pub-id-type="pmid">26468008</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cillóniz</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Ewig</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Polverino</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Muñoz-Almagro</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Marco</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Gabarrús</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes</article-title>. <source>Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis</source>. <year>2012</year> <month>Nov</month>;<volume>18</volume>(<issue>11</issue>):<fpage>1134</fpage>–<lpage>42</lpage>.</mixed-citation></ref>
<ref id="pone.0200504.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fatykhova</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Rabes</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Machnik</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Guruprasad</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Pache</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Berg</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Serotype 1 and 8 Pneumococci Evade Sensing by Inflammasomes in Human Lung Tissue</article-title>. <source>PloS One</source>. <year>2015</year>;<volume>10</volume>(<issue>8</issue>):<fpage>e0137108</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0137108" xlink:type="simple">10.1371/journal.pone.0137108</ext-link></comment> <object-id pub-id-type="pmid">26317436</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dela Cruz</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Wunderink</surname> <given-names>RG</given-names></name>, <name name-style="western"><surname>Christiani</surname> <given-names>DC</given-names></name>, <name name-style="western"><surname>Cormier</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Crothers</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Doerschuk</surname> <given-names>CM</given-names></name>, <etal>et al</etal>. <article-title>Future Research Directions in Pneumonia: NHLBI Working Group Report</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2018</year> <month>Mar</month> <day>16</day>;</mixed-citation></ref>
<ref id="pone.0200504.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kurt</surname> <given-names>OK</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Pinkerton</surname> <given-names>KE</given-names></name>. <article-title>Pulmonary health effects of air pollution</article-title>. <source>Curr Opin Pulm Med</source>. <year>2016</year> <month>Mar</month>;<volume>22</volume>(<issue>2</issue>):<fpage>138</fpage>–<lpage>43</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/MCP.0000000000000248" xlink:type="simple">10.1097/MCP.0000000000000248</ext-link></comment> <object-id pub-id-type="pmid">26761628</object-id></mixed-citation></ref>
<ref id="pone.0200504.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sahuquillo-Arce</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Ibáñez-Martínez</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Hernández-Cabezas</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ruiz-Gaitán</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Falomir-Salcedo</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Menéndez</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Influence of environmental conditions and pollution on the incidence of Streptococcus pneumoniae infections</article-title>. <source>ERJ Open Res</source>. <year>2017</year> <month>Oct</month>;<volume>3</volume>(<issue>4</issue>).</mixed-citation></ref>
<ref id="pone.0200504.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Woodhead</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Welch</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Harrison</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Bellingan</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Ayres</surname> <given-names>JG</given-names></name>. <article-title>Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database</article-title>. <source>Crit Care Lond Engl</source>. <year>2006</year>;<volume>10</volume> <issue>Suppl 2</issue>:<fpage>S1</fpage>.</mixed-citation></ref>
<ref id="pone.0200504.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Woodhead</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Blasi</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Ewig</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Garau</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Huchon</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Ieven</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Guidelines for the management of adult lower respiratory tract infections—full version</article-title>. <source>Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis</source>. <year>2011</year> <month>Nov</month>;<volume>17</volume> <issue>Suppl 6</issue>:<fpage>E1</fpage>–<lpage>59</lpage>.</mixed-citation></ref>
<ref id="pone.0200504.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mandell</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Bartlett</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Dowell</surname> <given-names>SF</given-names></name>, <name name-style="western"><surname>File</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Musher</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Whitney</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults</article-title>. <source>Clin Infect Dis Off Publ Infect Dis Soc Am</source>. <year>2003</year> <month>Dec</month> <day>1</day>;<volume>37</volume>(<issue>11</issue>):<fpage>1405</fpage>–<lpage>33</lpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>